On 8 October 2026, Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX:PAR) released an announcement titled Further Obsidian Note Redemption and Phase 3 Data Review Update. The company reported the redemption of further convertible notes held by Obsidian Global GP, LLC and an update on its review of Phase 3 clinical data.

Further redemption of Obsidian convertible notes

Following discussions with Obsidian, the parties agreed to redeem and cancel a further 1,171,477 convertible notes for a cash payment of US$1,404,600, approximately A$2 million. The notes were redeemed and cancelled on completion of payment, leaving 3,125,708 convertible notes outstanding.

The redemption is made under the Convertible Securities Agreement and Share Placement Agreement dated on or about 1 July 2025 and a Deed of Variation dated on or about 29 April 2026, together described as the CSA. The company noted the CSA has granted a general security agreement over its assets.

Phase 3 data review

The company said the initial review of the Phase 3 PARA_OA_012 clinical data by unblinded Paradigm staff highlights missing data at important time points, which is a key Factor in the interim results. The missing data is more frequent at US sites.

Initial observations in the rest-of-world dataset, comprising Australia, Moldova and Hong Kong, were described as appearing encouraging. The announcement states these observations remain preliminary and do not establish efficacy, and that independent analysis commissioned by Paradigm, not yet received, may reach different conclusions.

Status of the trial, administration and trading

Paradigm stated that these internal observations do not change the previously announced decision that the Phase 3 trial will not proceed. It expects to provide a further update in the coming weeks, subject to completion of the independent statistical analysis.

Voluntary administrators from FTI Consulting were appointed to the company on 29 September 2026, and the company’s securities remain suspended from trading. The announcement was authorised for release by the Voluntary Administrators.

Sector backdrop

Late-stage Clinical Trials depend on complete, high-quality data at pre-specified time points. Missing data can complicate statistical analysis, and sponsors often commission independent analysis to test how results are affected by data gaps and by differences between regions.

When a listed company enters voluntary administration, ASX securities are typically suspended while administrators assess the company’s position and options, and creditors, including secured creditors, play a central role in the outcome.

Risks shareholders should weigh

The company is under voluntary administration and its securities are suspended, so shareholders cannot trade them while that status continues. The outcome for shareholders will depend on the administrators’ process and the position of creditors.

The CSA includes a general security agreement over the company’s assets, and 3,125,708 convertible notes remain outstanding after the redemption. The announcement does not describe how the remaining notes will be treated.

The Phase 3 observations are preliminary, do not establish efficacy and rely on internal review of data with gaps at key time points. The trial will not proceed, and independent analysis may reach different conclusions.

What’s next

Paradigm expects to provide a further update on the data in the coming weeks, subject to completion of the independent statistical analysis and review of its findings. Further information is expected from the Voluntary Administrators on the administration process, and securities remain suspended.